Germany - Drugs

Description

§ Section 130a (8) SGB V enables health insurance funds (KK) and pharmaceutical companies to conclude framework discount agreements on drugs to be dispensed at the expense of the statutory KK. GWQ acts as a company for efficiency and quality at KK according to § 130a Abs. 8 S. 5 SGBV for its shareholder and customer health insurance companies. With regard to the relevant legal regulations for the award of public contracts, a regular process of active ingredient-related, formal award procedures in accordance with the regulations of the 4th part of the GWB is carried out by GWQ ServicePlus AG. Until the entry into force of new drug rebate contracts, GWQ would like to conclude drug rebate contracts with all interested pharmaceutical companies. The start of the contract is 01.05.2023.
GWQ ServicePlus AG intends to conclude non-exclusive rebate agreements in accordance with Section 130a (8) SGB V for the above-mentioned active ingredient. All interested companies can join this agreement at any time during the term of the agreement under the same conditions (approval model). GWQ assumes that this procedure does not fall within the scope of antitrust law due to the lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. The contract documents, the participating health insurance companies and their sales as well as the dates for notification of the contract can be viewed and downloaded from the contract award portal of GWQ ServicePlus AG at http://vergabeportal.gwq-serviceplus.de. Until the start of exclusive contracts, this transitional agreement is open to all market participants to join.Upon receipt of the signed contracts / declaration and evidence by 10.04.2023, an initial notification can be realized on 01.05.2023.The following documents must be submitted:- signed contract in duplicate;- a proof of drug regulatory approval by means of an extract from the public part of the AMIce database;- signed self-declaration (Annex 3)- PZN list (Annex 4)- declaration on prescription (Annex 5).

Opportunity closing date

10 November 2024

Value of contract

£0-100k